Navigating FDA’s Real-World Biocompatibility Expectations 

Bringing a novel medical device from the whiteboard to the operating room is an exhilarating journey, but it frequently hits an abrupt wall at regulatory review. Developers often assume that running a standard battery of laboratory tests will automatically satisfy agency reviewers. In reality, the FDA does not evaluate safety in a vacuum; they evaluate … Read more

How CGMP Violations Brought Down Happy Farm Botanicals 

Receiving an official Warning Letter from the FDA is a defining moment that can permanently shatter a company’s reputation and bottom line. For Happy Farm Botanicals, Inc., an over-the-counter (OTC) drug manufacturer based in Hyattsville, Maryland, a September 1, 2026, warning letter proved to be the final straw. What began as routine compliance oversight ended … Read more